- Home
- BIAF vs PIRS Comparison
BIAF vs PIRS Comparison
Compare BIAF & PIRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- PIRS
- Stock Information
- Founded
- BIAF 2014
- PIRS 2001
- Country
- BIAF United States
- PIRS United States
- Employees
- BIAF N/A
- PIRS N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PIRS Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- PIRS Health Care
- Exchange
- BIAF Nasdaq
- PIRS Nasdaq
- Market Cap
- BIAF 21.4M
- PIRS 22.4M
- IPO Year
- BIAF 2022
- PIRS N/A
- Fundamental
- Price
- BIAF $1.24
- PIRS $15.93
- Analyst Decision
- BIAF Strong Buy
- PIRS
- Analyst Count
- BIAF 1
- PIRS 0
- Target Price
- BIAF $6.00
- PIRS N/A
- AVG Volume (30 Days)
- BIAF 102.5K
- PIRS 37.6K
- Earning Date
- BIAF 11-14-2024
- PIRS 11-13-2024
- Dividend Yield
- BIAF N/A
- PIRS N/A
- EPS Growth
- BIAF N/A
- PIRS N/A
- EPS
- BIAF N/A
- PIRS N/A
- Revenue
- BIAF $9,367,785.00
- PIRS $1,352,000.00
- Revenue This Year
- BIAF $302.41
- PIRS N/A
- Revenue Next Year
- BIAF $15.00
- PIRS N/A
- P/E Ratio
- BIAF N/A
- PIRS N/A
- Revenue Growth
- BIAF 2813.87
- PIRS N/A
- 52 Week Low
- BIAF $1.20
- PIRS $6.20
- 52 Week High
- BIAF $3.62
- PIRS $22.32
- Technical
- Relative Strength Index (RSI)
- BIAF 36.67
- PIRS 43.29
- Support Level
- BIAF $1.21
- PIRS $15.15
- Resistance Level
- BIAF $1.37
- PIRS $16.97
- Average True Range (ATR)
- BIAF 0.08
- PIRS 0.72
- MACD
- BIAF 0.01
- PIRS -0.08
- Stochastic Oscillator
- BIAF 17.50
- PIRS 30.75
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About PIRS Pieris Pharmaceuticals Inc.
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.